Brean Capital analyst Jonathan Aschoff maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $22 price target, following the company’s third-quarter financial results and …
In a research note issued yesterday, H.C.
MLV analyst Arlinda Lee reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $16 price target, as the company reported third- quarter earnings of ($0.51) …
In a research report published today, Brean Capital analyst Jonathan Aschoff reaffirmed a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $22 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) and raised his price target …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $25 price target. …
In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a price target …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $19 price …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a price target …
TG Therapeutics (TGTX) announced the initiation of a novel three drug combination study assessing the chemo-free combination of TG-1101 + TGR-1202 + Imbruvica. …
